The
Canada Osteoporosis Treatment Drugs Market is anticipated to witness impressive
growth during the forecast period. This can be ascribed to the growing
prevalence of osteoporosis among women and aging people across the country.
Additionally, an increase in the demand for better diagnosis of osteoporosis is
anticipated to drive the growth of the Canada Osteoporosis Treatment Drugs
Market during the forecast period. Moreover, the high concentration of market
players or manufacturers' presence, and acquisition & partnerships among
major players for the development of new drugs for the treatment of
osteoporosis are expected to create lucrative growth in the Canada Osteoporosis
Treatment Drugs Market during the forecast period. Similarly, growing
initiatives taken by the government and private associations through various
programs and campaigns to educate people and raise awareness about new drugs
are anticipated to drive the growth of the market over the years.
Growing Aging Population
The
aging population has a significant influence on the growth of the Canada
osteoporosis treatment drugs market. As the population ages, the prevalence of
osteoporosis increases, leading to a higher demand for effective treatment
options. Osteoporosis is more prevalent among older adults, particularly
postmenopausal women and older men. As the population in Canada continues to
age, the number of individuals at risk of developing osteoporosis rises. This
demographic shift leads to a larger patient pool requiring osteoporosis
treatment drugs, driving the growth of the market.
Aging
is associated with an increased risk of fractures, especially fragility
fractures resulting from weakened bones. Osteoporosis significantly contributes
to the risk of fractures in older adults. With a growing aging population, the
incidence of osteoporotic fractures is expected to rise, necessitating
effective treatment drugs to manage fractures and prevent future occurrences.
Osteoporosis
is a chronic condition that requires long-term treatment and management. As
individuals live longer due to improved healthcare and advancements in medical
technology, the duration of treatment for osteoporosis also increases. This
prolongs the demand for osteoporosis treatment drugs, as patients require
continuous medication to maintain bone health and reduce the risk of fractures.
The
aging population places a significant burden on healthcare systems, including
the cost of managing osteoporosis and associated complications. Osteoporosis-related
fractures can lead to hospitalizations, surgeries, and rehabilitation,
resulting in substantial healthcare expenditures. This economic impact drives
the need for effective treatment drugs to mitigate the financial burden on
individuals and the healthcare system.
With
a larger aging population, there is an increased emphasis on healthy aging and
quality of life. Untreated osteoporosis can severely impact mobility,
independence, and overall well-being in older adults. The desire to maintain an
active and independent lifestyle motivates individuals to seek osteoporosis
treatment options, creating a demand for effective drugs that can improve bone
health and prevent fractures.
Rising prevalence of osteoporosis
The
increasing prevalence of osteoporosis plays a crucial role in influencing the
growth of the Canadian osteoporosis treatment drugs market. As the prevalence
of osteoporosis increases, there is a greater demand for effective treatment
options to manage the condition. Moreover, as the prevalence of osteoporosis
rises, the number of individuals affected by the condition also increases. This
larger patient pool drives the demand for osteoporosis treatment drugs. More
individuals requiring treatment create opportunities for pharmaceutical companies
to develop and market their products, leading to market growth.
With
growing awareness and improved screening practices, the diagnosis rates of
osteoporosis have been on the rise. Early detection of osteoporosis is crucial
for effective management and prevention of fractures. As more individuals are
diagnosed with osteoporosis, there is a higher demand for treatment drugs to
address their healthcare needs. The rising prevalence of osteoporosis has
prompted a greater focus on preventive measures. Healthcare professionals and
public health campaigns emphasize the importance of lifestyle modifications,
adequate nutrition, calcium and vitamin D supplementation, and regular exercise
to prevent osteoporosis. These preventive efforts contribute to the demand for
treatment drugs that support preventive strategies.
Osteoporosis
is associated with an increased risk of fractures, which can have a significant
impact on an individual's health, well-being, and quality of life. The rising
prevalence of osteoporosis also means a higher burden of osteoporotic fractures
on healthcare systems. The need for effective treatment drugs to manage
fractures and reduce their occurrence drives the growth of the osteoporosis
treatment drugs market.
The
prevalence of osteoporosis increases with age, and Canada has a rapidly aging
population. As the population continues to age, the prevalence of osteoporosis
is expected to rise further. The aging population presents a significant market
opportunity for osteoporosis treatment drugs, as older adults are more
susceptible to the condition and require appropriate management and treatment
options.
The
rising prevalence of osteoporosis has led to increased research and development
efforts to discover innovative treatment options. Pharmaceutical companies
invest in developing new drugs, formulations, and therapeutic approaches to
address the growing healthcare needs associated with osteoporosis. The focus on
research and development fuels the growth of the market and drives innovation
in the field.
Increasing awareness about osteoporosis
Increasing
about osteoporosis has a significant impact on the growth of the Canadian
osteoporosis treatment drugs market. As awareness about the condition improves,
more individuals recognize the importance of early diagnosis, prevention, and
appropriate treatment, leading to increased demand for osteoporosis treatment
drugs. Improved awareness about osteoporosis leads to early detection and
diagnosis of the condition. Individuals who are aware of the risk factors and
symptoms of osteoporosis are more likely to seek medical attention and undergo
appropriate screening tests. Early detection allows for timely intervention and
treatment, creating a greater demand for osteoporosis treatment drugs. As
individuals become more aware of the consequences of untreated osteoporosis,
there is an increased demand for effective treatment options. People recognize
the importance of managing the condition to reduce the risk of fractures and
maintain bone health. This demand for treatment drugs drives the growth of the
osteoporosis treatment drugs market. Increased awareness empowers patients to
take an active role in managing their osteoporosis. Well-informed patients are
more likely to adhere to prescribed treatment plans, follow lifestyle
recommendations, and engage in preventive measures. This patient empowerment
contributes to better treatment outcomes and encourages the utilization of
osteoporosis treatment drugs. Awareness about osteoporosis prompts healthcare
providers to prioritize the condition and incorporate appropriate screening and
treatment practices. Physicians and other healthcare professionals become more
knowledgeable about osteoporosis management, leading to increased discussions,
referrals, and prescriptions for osteoporosis treatment drugs. This engagement
from healthcare providers drives the growth of the market. Awareness campaigns
and public health initiatives play a crucial role in disseminating information
about osteoporosis. These initiatives, led by healthcare organizations, patient
advocacy groups, and government entities, focus on raising public awareness,
promoting preventive measures, and educating individuals about osteoporosis and
its management. Such efforts generate interest in osteoporosis treatment drugs
and contribute to market growth.
Technological advancements
Technological
advancements play a crucial role in influencing the growth of the Canadian
osteoporosis treatment drugs market. These advancements contribute to the
development of new and improved treatment options, enhance the efficacy and
safety of drugs, and improve patient outcomes. Technological advancements, such
as high-throughput screening methods, computer modeling, and virtual screening
techniques, accelerate the drug discovery and development process. These
advancements enable researchers to identify potential drug candidates more
efficiently, reducing the time and cost involved in bringing new osteoporosis
treatment drugs to the market. Advancements in pharmaceutical technology allow for
the development of novel drug formulations with improved characteristics.
Controlled-release formulations, combination therapies, and novel delivery
systems enhance the efficacy, safety, and convenience of osteoporosis treatment
drugs. Such innovations contribute to market growth by providing patients and
healthcare providers with more options for effective drug administration.
Technological advancements have facilitated the identification and utilization
of biomarkers in osteoporosis management. Biomarkers, such as bone turnover
markers, genetic markers, and imaging techniques, help assess disease severity,
treatment response, and individualized risk prediction. The integration of
biomarkers into clinical practice supports personalized medicine approaches,
optimizing treatment choices and improving patient outcomes. Imaging
technologies, such as dual-energy X-ray absorptiometry (DXA), have
revolutionized osteoporosis diagnosis and monitoring. DXA scans provide
accurate measurements of bone mineral density (BMD) and aid in assessing
fracture risk. Technological advancements in imaging techniques, including
improved resolution and 3D imaging capabilities, enhance the precision and
reliability of osteoporosis diagnosis, allowing for targeted treatment interventions.
The emergence of digital health technologies has transformed healthcare
delivery, including the management of osteoporosis. Mobile applications,
wearable devices, and remote monitoring systems enable better self-management,
medication adherence, and patient engagement. These digital health solutions
provide real-time data, facilitate communication between patients and
healthcare providers, and contribute to more effective treatment strategies.
Supportive government initiatives
Supportive
government initiatives play a crucial role in influencing the growth of the
Canada osteoporosis treatment drugs market. These initiatives encompass various
policies, programs, and funding support that aim to improve access to
healthcare, enhance patient outcomes, and address the healthcare needs of
individuals with osteoporosis. Government initiatives can include public
healthcare funding and reimbursement policies that support access to
osteoporosis treatment drugs. Public health insurance plans or drug reimbursement
programs cover a portion of the cost of prescribed medications, making them
more affordable and accessible to patients. This encourages the utilization of
osteoporosis treatment drugs and drives market growth. Government initiatives
often involve health education and awareness campaigns to inform the public
about osteoporosis, its risk factors, and the importance of early detection and
treatment. These campaigns help raise awareness among individuals, healthcare
providers, and communities, leading to increased demand for osteoporosis
treatment drugs as more people seek appropriate care and management. Government
bodies, in collaboration with healthcare professionals, develop clinical
practice guidelines for the management of osteoporosis. These guidelines
provide evidence-based recommendations on diagnosis, treatment, and follow-up
care. By promoting standardized and effective treatment practices, government
initiatives contribute to the utilization of osteoporosis treatment drugs and
drive market growth. Government funding support for research and development in
the field of osteoporosis stimulates innovation and advancements in treatment
options. Research grants and collaborative initiatives encourage academic
institutions, pharmaceutical companies, and healthcare providers to explore new
therapies, drug formulations, and treatment strategies. This promotes market
growth by fostering the development of innovative osteoporosis treatment drugs.
Governments play a crucial role in establishing regulatory frameworks for the
approval, safety, and quality assurance of pharmaceutical products, including
osteoporosis treatment drugs. These frameworks ensure that drugs meet stringent
standards for efficacy, safety, and manufacturing practices. A robust regulatory
environment instills confidence in patients, healthcare providers, and
pharmaceutical companies, supporting the growth and credibility of the market. Governments
collaborate with various stakeholders, including patient advocacy groups,
healthcare providers, and pharmaceutical companies, to address the challenges
associated with osteoporosis management. These collaborations aim to improve
treatment pathways, access to care, and patient outcomes. By fostering
collaboration, government creates an environment that promotes the growth and
development of the osteoporosis treatment drugs market in the country.
Recent Developments
- Evenity is
an injectable monoclonal antibody that was approved by Health Canada in
2019 for the treatment of osteoporosis in postmenopausal women at high
risk of fractures. It works by increasing bone formation and reducing bone
resorption. Evenity is typically administered as a once-monthly injection
for a specific treatment duration.
- · Aclasta,
also known as Reclast in some countries, is an intravenous bisphosphonate
that has been available in Canada for the treatment of osteoporosis for
several years. It is administered as a once-yearly infusion and helps
reduce bone loss and decrease the risk of fractures in postmenopausal
women and men with osteoporosis.
- Prolia is a
subcutaneous injection that was approved for the treatment of osteoporosis
in Canada. It works by inhibiting the activity of osteoclasts, which are
cells responsible for bone resorption. Prolia is typically administered
once every six months and is indicated for postmenopausal women at high
risk of fractures and for men with osteoporosis at an increased fracture
risk.
Market Segmentation
The
Canada Osteoporosis Treatment Drugs Market can be categorized by Drug Class,
Route of Administration, Distribution Channel, Region and Competitive Landscape.
In terms of Drug Class, the market in Canada can be classified into
Bisphosphonate, Hormone Replacement Therapy, Selective Estrogen Receptor
Modulator, Rank Ligand Inhibitor, and Others. Regarding Route of
Administration, the market can be divided into Oral and Parenteral. As for
Distribution Channel, the market in Canada can be segmented into Hospital
Pharmacies, Retail Pharmacies and Stores, and Online Pharmacies.
Market Players
AbbVie
Inc, Eli Lilly Canada Inc, Amgen Canada Inc, Hoffmann-La Roche Ltd, Novartis
Pharmaceuticals Canada Inc, Sanofi-Aventis Canada Inc, Pfizer Canada Inc,
GlaxoSmithKline Inc/Canada are some of the leading players operating in the Canada
Osteoporosis Treatment Drugs Market.
|
Attribute
|
Details
|
|
Base
Year
|
2022
|
|
Historic
Data
|
2018 – 2021
|
|
Estimated
Year
|
2023
|
|
Forecast
Period
|
2024 – 2028
|
|
Quantitative
Units
|
Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028
|
|
Report
Coverage
|
Revenue
forecast, company share, competitive landscape, growth factors, and trends
|
|
Segments
Covered
|
By Drug Class
By Route of
Administration
By Distribution
Channel
By Region
|
|
Regional
scope
|
Ontario
region; Quebec region; Alberta region; British Columbia region; Saskatchewan
and Manitoba region; Rest of Canada
|
|
Key
companies profiled
|
AbbVie Inc, Eli
Lilly Canada Inc, Amgen Canada Inc, Hoffmann-La Roche Ltd, Novartis
Pharmaceuticals Canada Inc, Sanofi-Aventis Canada Inc, Pfizer Canada Inc,
GlaxoSmithKline Inc/Canada
|
|
Customization
scope
|
10%
free report customization with purchase. Addition or alteration to country,
regional & segment scope.
|
|
Pricing
and purchase options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery
Format
|
PDF and Excel through Email (We can also provide the editable
version of the report in PPT/Word format on special request)
|
Report
Scope:
In this
report, the Canada Osteoporosis Treatment Drugs Market has been segmented into the
following categories, in addition to the industry trends which have also been
detailed below:
- Canada Osteoporosis Treatment Drugs
Market, By Drug Class:
o Bisphosphonate
o Hormone Replacement Therapy
o Selective Estrogen Receptor Modulator
o Rank Ligand Inhibitor
o Others
- Canada Osteoporosis Treatment Drugs
Market, By Route of Administration:
o Oral
o Parenteral
- Canada Osteoporosis Treatment Drugs
Market, By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies and stores
o Online Pharmacies
- Canada Osteoporosis Treatment Drugs
Market, By Region:
o
Ontario region
o Quebec region
o Alberta region
o British Columbia region
o Saskatchewan and Manitoba region
o Rest of Canada
Competitive
Landscape
Company
Profiles: Detailed analysis of the major
companies present Canada Osteoporosis Treatment Drugs Market.
Available
Customizations:
With
the given market data, TechSci Research offers customizations according to a
company’s specific needs. The following customization options are available for
the report:
Company
Information
- Detailed analysis and profiling of
additional market players (up to five).
Canada Osteoporosis Treatment Drugs Market is an
upcoming report to be released soon. If you wish an early delivery of this
report or want to confirm the date of release, please contact us at [email protected]